LUTATHERA

Google image searchProduct monograph

Active ingredient

lutetium (177lu) oxodotreotide, 370 MBq/ML

DIN: 02484552

Dosage form(s): SOLUTION

Route(s) of administration: INTRAVENOUS

Description: SINGLE-DOSE VIAL

Schedule: Schedule C

Company: NOVARTIS PHARMACEUTICALS CANADA INC

Date: 28-FEB-2024

ATC:

• V10 — THERAPEUTIC RADIOPHARMACEUTICALS (ATC, ATC/DDD, )
• V10X — OTHER THERAPEUTIC RADIOPHARMACEUTICALS (ATC, ATC/DDD)
• V10XX — Various therapeutic radiopharmaceuticals (ATC, ATC/DDD)
• V10XX04 — LUTETIUM (177Lu) OXODOTREOTIDE (ATC/DDD)

Pharmaceutical standard: MFR

External Links for Lutathera

Search on Google

• Lutathera side effects
• Lutathera dosage
• lutetium side effects
• lutetium dosage

Novartis Pharmaceuticals Canada Inc

Go to Novartis website to see drug product details. Sometimes you can find lutathera photos and/or monograph. If you are a healthcare professional, you may need to enter your license number.